Thyroid Nodules: Surgery vs Radiofrequency Ablation vs Monitoring

The Monitoring Default

Over 95% of thyroid nodules are benign. Fine-needle aspiration (FNA) biopsy determines this. A confirmed benign nodule (Bethesda II) has a less than 3% false-negative rate and can be monitored with ultrasound at 12 to 24 month intervals. Most patients never need treatment.

Treatment enters the picture when a benign nodule grows large enough to cause symptoms (typically over 3 to 4 cm), causes cosmetic concerns, or when growth pattern raises uncertainty about the initial biopsy.

Surgery: The Definitive Option

Thyroid lobectomy (removing half the gland) or total thyroidectomy (removing the entire gland) eliminates the nodule permanently. Lobectomy preserves thyroid function in about 70% to 80% of patients. Total thyroidectomy requires lifelong levothyroxine replacement.

Surgery is required for: confirmed or suspected malignancy (Bethesda V-VI), nodules with indeterminate biopsy (Bethesda III-IV) depending on molecular testing, retrosternal extension, and patient preference for definitive treatment.

Radiofrequency Ablation: The Emerging Middle

RFA uses a needle-like electrode inserted into the nodule under ultrasound guidance. Radiofrequency energy heats and destroys nodule tissue, which the body gradually absorbs. The thyroid gland remains intact. No general anesthesia is required in most cases.

Korean and Italian centers with the most experience report 50% to 80% volume reduction at 12 months, with symptom resolution in over 90% of properly selected patients. The technique has been endorsed by the Korean Thyroid Association and the European Thyroid Association for symptomatic benign nodules.

Decision Framework

Benign nodule, no symptoms, stable on ultrasound: continue monitoring. Benign nodule causing symptoms or cosmetic concern, patient wants to keep thyroid function: RFA is a strong option. Malignant or suspicious nodule: surgery. Indeterminate biopsy: molecular testing first, then surgery or monitoring depending on risk stratification. The key is that RFA fills a gap that did not exist a decade ago: effective treatment without gland removal for the right patient.

Who Is Not a Candidate for RFA

RFA is not appropriate for every thyroid nodule. Exclusion criteria include: confirmed malignancy (Bethesda V-VI) unless the patient cannot tolerate surgery and the cancer is low-risk, suspicious biopsy (Bethesda IV) without molecular testing to clarify, nodules with significant extracapsular extension, severely calcified nodules (which resist heat penetration and reduce efficacy), and nodules compressing the trachea to the point where the swelling caused by the ablation could worsen airway compromise. A repeat FNA confirming benign status is typically required within 6 months of the planned RFA.

Patient selection is the single most important factor in RFA outcomes. Centers reporting the best results are also the most selective about which nodules they treat. A center that offers RFA for every nodule regardless of characteristics should raise questions.

The Practical Experience of Each Treatment

Understanding what each option actually involves from the patient's perspective can help with the decision. Monitoring means an ultrasound every 12 to 24 months. The anxiety of watching a nodule grow, even when benign, is a real psychological burden that guidelines do not adequately address. Some patients find monitoring intolerable and choose treatment for peace of mind, which is a valid reason.

RFA is performed as an outpatient procedure under local anesthesia and mild sedation. The patient lies on a table with the neck extended. Ultrasound guides the needle electrode into the nodule. Treatment takes 10 to 30 minutes depending on nodule size. Patients feel warmth or mild pressure. Post-procedure, there may be neck swelling, mild pain, and bruising for a few days. Voice changes are rare (<1%) and usually temporary. There are no activity restrictions, and most patients return to work the next day.

Thyroid surgery requires general anesthesia, a 4 to 6 cm neck incision (or smaller incisions for robotic approaches), and 1 to 2 days of hospitalization. Recovery takes 1 to 2 weeks for desk work, 3 to 4 weeks for physical activity. The neck scar fades significantly over 6 to 12 months. Risks include recurrent laryngeal nerve injury (voice change, 1-2% temporary, <1% permanent) and hypoparathyroidism (calcium regulation disruption, 1-5% temporary, <1% permanent). Total thyroidectomy requires daily levothyroxine for life; the dose is usually straightforward to manage but requires periodic blood testing.

Emerging Alternatives

Ethanol ablation (percutaneous ethanol injection, PEI) is an older, cheaper alternative to RFA that works well for cystic or predominantly cystic nodules (those that are mostly fluid-filled). For solid nodules, PEI is less effective and less predictable than RFA. Laser ablation and microwave ablation are other thermal techniques with similar efficacy to RFA in smaller studies but less long-term data. High-intensity focused ultrasound (HIFU) is a completely noninvasive option under investigation but not yet widely available or well-validated for thyroid nodules.

The thyroid treatment landscape is evolving rapidly. Techniques that are "emerging" today may become standard within 5 years. For patients whose nodules are not causing acute problems, monitoring while the evidence base matures is a reasonable strategy. For patients with significant symptoms or cosmetic concerns now, RFA at an experienced center offers an established, well-studied option.